Morpho Biotech is spearheading the European expansion, moving beyond its existing footprint in Belgium, Luxembourg, and the Netherlands to now cover Germany and France. The firm intends to leverage its regional expertise to transition labs toward iconPCR’s automated workflows, which replace traditional, labor-intensive cleanup and pooling methods. Koos Kranenborg, General Manager of Morpho Biotech, noted that the platform’s ability to control amplification at the individual-sample level is already proving to be a significant technical standard for NGS library preparation.

Beyond Europe, n6 is establishing a presence in emerging markets through partnerships with Bioseen Trading LLC in the Gulf Region and Inqaba Biotec across Africa. These additions complement an existing network that includes Witec, Bonsai Lab, and others. The company is backing this commercial growth with a series of technical workshops scheduled through the end of 2026, including sessions at the EMBL conference in Heidelberg. By integrating amplification, quantification, and normalization into a single automated step, n6 aims to reduce failure rates for applications ranging from FFPE oncology to microbiome studies, providing local support teams to help laboratories scale their throughput.